Radius Health to Announce Fourth Quarter and Full Year 2015 Financial Results, Host Conference Call and Live Webcast on February 25, 2016

WALTHAM, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its fourth quarter and full year 2015 financial results on Thursday, February 25, 2016.

In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 7:30 a.m. ET on Thursday, February 25, 2016 to discuss the results.

Conference Call Information:

Date: Thursday, February 25, 2016

Time: 7:30 a.m. ET

Domestic Dial-in Number: 1-877-705-6003

International Dial-in Number: 1-201-493-6725

Live webcast: http://public.viavid.com/player/index.php?id=118001

For those unable to participate in the conference call or webcast, a replay will be available beginning February 25, 2016 at 10:30 a.m. ET until March 10, 2016 at 11:59 p.m. ET. To access the replay, dial 1-877-870-5176 or 1-858-384-5517. The replay pin number is 13629094.

A live audio webcast of the call will also be available on the Investors section of the Company's website, www.radiuspharm.com. A webcast replay will be available for 14 days on the Radius website, www.radiuspharm.com. The full text of the announcement and financial results will also be available on the Company's website.

About Radius
Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. Radius' preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential applications in oncology. For more information, please visit www.radiuspharm.com.

CONTACT: Investor Relations Barbara Ryan 203-274-2825 bryan@radiuspharm.com Media Alice Pomponio V.P. Corporate Affairs 617-551-4099 apomponio@radiuspharm.com

Source:Radius Health Inc.